Mild Cognitive Impairment Clinical Trial
Official title:
Can Methylphenidate (Ritalin) Improve Memory and Attention in Mild Cognitive Impairment? A Combined Behaviour-EEG Study
Traditionally, memory impairments in the elderly population are treated using cholinesterase
inhibitors, although impairments remain after treatment. Dopamine (DA) is also involved in
cognition and is especially of interest in healthy ageing because of the role in processing
speed and cognitive control. To what extent dopamine treatment improves memory and attention
in older impaired individuals is unknown. However, such an effect is conceivable because of
the close relationship between memory and attention in aging and since improved processing
speed and cognitive control may lead to improved memory.
The investigators aim to examine, in the impaired older population, whether a treatment
using methylphenidate, a DA re-uptake inhibitor that enhances DA, improves attention and
memory. The study will be conducted according to a cross-sectional, double-blind,
placebo-controlled, 2-way cross-over design. 20 male and female patients with Mild Cognitive
Impairment (MCI), amnestic type, aged above 60 years of age; 20 male and female patients
with MCI, non-amnestic type, will be recruited from the Orbis Medical Centre. Participants
will be treated once with 20 mg methylphenidate (MPH) and once with placebo. All medications
will be administered orally with a capsule. The treatment order will be established by
counterbalancing.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years to 80 Years |
Eligibility |
Inclusion Criteria: - The participant has been diagnosed with Mild Cognitive Impairment, either of the amnestic or the non-amnestic type. - In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements. - The participant signs and dates a written informed consent form. - The volunteer is male or female. - The participant is aged 60 to 80 years, inclusive, at the time of informed consent. - The participant has a body mass index of 18.5-30, inclusive, at medical screening. - The volunteer is healthy, i.e. absence of all exclusion criteria and has normal static binocular acuity (corrected or uncorrected) as well as normal hearing (using a whisper test during medical screening). Exclusion Criteria: - The subject has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality which may impact the ability of the subject to participate or potentially confound the study results. - The volunteer has uncontrolled existing major psychiatric symptoms. - The subject has uncontrolled hypertension. - The volunteer has hyperthyroidism. - The participant has known hypersensitivity to any component of the formulation of MPH or related compounds. - The participant has glaucoma. - The subject has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the first visit or is unwilling to agree to abstrain from alcohol from 24 hours prior to each test day and/or drugs throughout the study. - The participant has any sensory or motor deficits which could reasonably be expected to affect test performance. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Netherlands | Orbis Medical Centre | Sittard-Geleen | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center | Orbis Medical Centre |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Verbal Learning Test Immediate Recall | 140 min after drug intake | No | |
Primary | Verbal Learning Test Delayed Recall | 175 min after drug intake | No | |
Primary | Verbal Learning Test Recognition | Accuracy and reaction time | 180 min after drug intake | No |
Primary | Amplitude of the N400 and P600 event-related potential (ERP) components | during encoding and recognition of words of VLT, measured with EEG | 140-190 min after drug intake | No |
Secondary | Performance on visual and auditory N-back test | 150 minutes after drug intake | No | |
Secondary | Performance on a sustained attention to response task (SART) | 165 minutes after drug intake | No | |
Secondary | Performance on a motor task | 170 minutes after drug intake | No | |
Secondary | Amplitude of ERP components during the visual and auditory N-back test | 150-165 minutes after drug intake | No | |
Secondary | Amplitude of ERP components during SART | 165 - 170 minutes after drug intake | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |